日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

一项针对先前接受过治疗的晚期非小细胞肺癌患者的 foretinib 联合 erlotinib 治疗的 I 期研究:加拿大癌症试验组 IND.196

Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, Dongsheng Tu, Cheryl Ho, Frances A Shepherd, Nevin Murray, John R Goffin, Garth Nicholas, Shingo Sakashita, Zhuo Chen, Lucia Kim, Jean Powers, Lesley Seymour, Glenwood Goss, Penelope A Bradbury

A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer

局限性前列腺癌患者术前使用 figitumumab 的 II 期药效学研究

Kim N Chi, Martin E Gleave, Ladan Fazli, S Larry Goldenberg, Alan So, Christian Kollmannsberger, Nevin Murray, Anna Tinker, Michael Pollak

Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development

肺癌亚型的基因组和表观基因组景观各异,凸显了肿瘤发展过程中不同致癌途径的选择

William W Lockwood, Ian M Wilson, Bradley P Coe, Raj Chari, Larissa A Pikor, Kelsie L Thu, Luisa M Solis, Maria I Nunez, Carmen Behrens, John Yee, John English, Nevin Murray, Ming-Sound Tsao, John D Minna, Adi F Gazdar, Ignacio I Wistuba, Calum E MacAulay, Stephen Lam, Wan L Lam